Jeffrey Scott Sherman - 02 May 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Role: Chief Financial Officer
Signature: /s/ Ali Olivo, Attorney-in-Fact
Issuer symbol: NEO
Transactions as of: 02 May 2025
Net transactions value: +$150,104
Form type: 4
Filing time: 06 May 2025, 16:08:57 UTC
Previous filing: 25 Feb 2025
Next filing: 13 May 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sherman Jeffrey Scott	Chief Financial Officer	9490 NEOGENOMICS WAY, FORT MYERS	/s/ Ali Olivo, Attorney-in-Fact	06 May 2025	0001463145

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NEO	Common Stock	Purchase	$150,104	+20,000	+14%	$7.51	158,494	02 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NEO	Stock Option (Right to Buy)						249,169	02 May 2025	Common Stock	249,169	$11.62	Direct	F2
holding	NEO	Stock Option (Right to Buy)						73,016	02 May 2025	Common Stock	73,016	$19.65	Direct	F3
holding	NEO	Restricted Stock Unit						26,011	02 May 2025	Common Stock	26,011	$0.000000	Direct	F4, F5
holding	NEO	Performance Stock Unit						39,016	02 May 2025	Common Stock	39,016	$0.000000	Direct	F5, F6
holding	NEO	Stock Option (Right to Buy)						77,913	02 May 2025	Common Stock	77,913	$16.45	Direct	F7
holding	NEO	Performance Stock Unit						46,606	02 May 2025	Common Stock	46,606	$0.000000	Direct	F5, F8
holding	NEO	Restricted Stock Unit						59,382	02 May 2025	Common Stock	59,382	$0.000000	Direct	F5
holding	NEO	Restricted Stock Unit						31,071	02 May 2025	Common Stock	31,071	$0.000000	Direct	F5, F9
holding	NEO	Stock Option (Right to Buy)						214,900	02 May 2025	Common Stock	214,900	$13.05	Direct	F10, F11
holding	NEO	Restricted Stock Unit						126,476	02 May 2025	Common Stock	126,476	$0.000000	Direct	F5, F12

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This balance includes 1,430 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
F2	On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023.
F3	On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F4	On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F5	Once vested, the shares of common stock are not subject to expiration.
F6	On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F7	On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F8	On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company
F9	On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F10	This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F11	On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F12	On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.